Yu et al. evaluated the efficacy of the treatment of ch14.18 combined with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interleukin 2 (IL-2) for HR-NB. This evidence concerns the gene IL2 and neuroblastoma.